Payment overview · 2025
General Payments
$1,201.98
41 reported records · 10 companies
Healthcare provider profile · identity verified
Maan A Askar, MD
Allopathic & Osteopathic Physicians|Family Medicine · WARREN, MI · NPI 1053321117
Verified facts
What the public records show
CMS Open Payments records show Maan A Askar, MD received $1,201.98 in general payments during 2025 across 41 reported records.
Novo Nordisk Inc accounted for 38.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 170 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 206 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 539 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 206 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $458.45 | 38.1% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $321.15 | 26.7% | 9 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $89.54 | 7.5% | 4 | 2025 |
| BSN Medical Inc | Unresolved — no canonical attribution shown | $72.38 | 6.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $66.76 | 5.5% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $60.42 | 5.0% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $52.03 | 4.3% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $43.74 | 3.6% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.96 | 1.7% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.55 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,201.98 | 41 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $415.26 | 11 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $321.15 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $157.91 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $90.27 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $89.54 | 4 | 2025 |
Source payment records
|
|||||
| JOBST SPORT Normalized: jobst sport |
Device | BSN Medical Inc | $72.38 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $60.42 | 3 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $52.03 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $48.52 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $48.52 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $43.74 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $43.19 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $35.79 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $19.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 206 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 170 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 60 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 539 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
170 | 39 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
206 | 62 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
539 | 109 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
60 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
206 | 62 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1034 | 290 |
| Amlodipine Besylate | Amlodipine Besylate | 812 | 226 |
| Lisinopril | Lisinopril | 703 | 183 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 617 | 154 |
| Losartan Potassium | Losartan Potassium | 583 | 153 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 539 | 109 |
| Metoprolol Succinate | Metoprolol Succinate | 512 | 148 |
| Famotidine | Famotidine | 502 | 159 |
| Levothyroxine Sodium | Levothyroxine Sodium | 402 | 99 |
| Metformin Hcl | Metformin Hcl | 359 | 93 |
| Carvedilol | Carvedilol | 354 | 93 |
| Metoprolol Tartrate | Metoprolol Tartrate | 257 | 69 |
| Furosemide | Furosemide | 252 | 79 |
| Hydralazine Hcl | Hydralazine Hcl | 250 | 72 |
| Tamsulosin Hcl | Tamsulosin Hcl | 242 | 71 |
| Methylprednisolone | Methylprednisolone | 237 | 174 |
| Clopidogrel | Clopidogrel Bisulfate | 231 | 75 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 229 | 72 |
| Simvastatin | Simvastatin | 224 | 52 |
| Eliquis | Apixaban | 206 | 62 |
| Omeprazole | Omeprazole | 194 | 60 |
| Gabapentin | Gabapentin | 185 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 183 | 42 |
| Ezetimibe | Ezetimibe | 178 | 41 |
| Potassium Chloride | Potassium Chloride | 174 | 54 |
| Farxiga | Dapagliflozin Propanediol | 170 | 39 |
| Ibuprofen | Ibuprofen | 168 | 61 |
| Januvia | Sitagliptin Phosphate | 166 | 41 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 160 | 49 |
| Ventolin Hfa | Albuterol Sulfate | 145 | 50 |
| Allopurinol | Allopurinol | 144 | 41 |
| Jardiance | Empagliflozin | 144 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 139 | 38 |
| Montelukast Sodium | Montelukast Sodium | 136 | 35 |
| Mirtazapine | Mirtazapine | 121 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 116 | 47 |
| Buspirone Hcl | Buspirone Hcl | 110 | 36 |
| Nifedipine Er | Nifedipine | 109 | 33 |
| Alendronate Sodium | Alendronate Sodium | 105 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 101 | 28 |
| Hydrocortisone | Hydrocortisone | 99 | 37 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 99 | 30 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 94 | 24 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 92 | 76 |
| Dicyclomine Hcl | Dicyclomine Hcl | 92 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 89 | 50 |
| Mounjaro | Tirzepatide | 83 | 17 |
| Linzess | Linaclotide | 81 | 25 |
| Oxybutynin Chloride | Oxybutynin Chloride | 80 | 27 |
| Finasteride | Finasteride | 78 | 26 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 75 | 19 |
| Primidone | Primidone | 75 | 17 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 74 | 25 |
| Donepezil Hcl | Donepezil Hcl | 74 | 25 |
| Meloxicam | Meloxicam | 74 | 27 |
| Novolog Flexpen | Insulin Aspart | 74 | 24 |
| Xarelto | Rivaroxaban | 74 | 24 |
| Pregabalin | Pregabalin | 73 | 14 |
| Meclizine Hcl | Meclizine Hcl | 72 | 26 |
| Glimepiride | Glimepiride | 71 | 19 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 68 | 29 |
| Sertraline Hcl | Sertraline Hcl | 66 | 19 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 65 | 27 |
| Trulicity | Dulaglutide | 61 | 18 |
| Ozempic | Semaglutide | 60 | 14 |
| Cephalexin | Cephalexin | 57 | 50 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 57 | 12 |
| Entresto | Sacubitril/Valsartan | 56 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 55 | 19 |
| Terazosin Hcl | Terazosin Hcl | 55 | 16 |
| Warfarin Sodium | Warfarin Sodium | 55 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | 19 |
| Bumetanide | Bumetanide | 49 | 13 |
| Topiramate | Topiramate | 48 | 11 |
| Aripiprazole | Aripiprazole | 44 | suppressed |
| Fenofibrate | Fenofibrate | 44 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 44 | 12 |
| Spironolactone | Spironolactone | 43 | 17 |
| Trazodone Hcl | Trazodone Hcl | 43 | 18 |
| Digoxin | Digoxin | 41 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 23 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 40 | suppressed |
| Azithromycin | Azithromycin | 40 | 28 |
| Glipizide | Glipizide | 39 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | 12 |
| Clonidine Hcl | Clonidine Hcl | 37 | suppressed |
| Fluconazole | Fluconazole | 37 | 22 |
| Valsartan | Valsartan | 37 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Levetiracetam | Levetiracetam | 35 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 35 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 32 | 11 |
| Divalproex Sodium | Divalproex Sodium | 31 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | 12 |
| Albuterol Sulfate | Albuterol Sulfate | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 29 | 21 |
| Methimazole | Methimazole | 29 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 29 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 28 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | 11 |
| Mupirocin | Mupirocin | 28 | 18 |
| Prednisone | Prednisone | 28 | 24 |
| Incruse Ellipta | Umeclidinium Bromide | 27 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Ketoconazole | Ketoconazole | 26 | suppressed |
| Clonidine | Clonidine | 25 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 23 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Modafinil | Modafinil | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 14 |
| Alprazolam | Alprazolam | 21 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 21 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 20 | 17 |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Klor-Con M10 | Potassium Chloride | 20 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 20 | 12 |
| Levemir Flexpen | Insulin Detemir | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 18 | 14 |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Rexulti | Brexpiprazole | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 12 |
| Cefuroxime | Cefuroxime Axetil | 15 | 14 |
| Celecoxib | Celecoxib | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | 11 |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 12 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Fondaparinux Sodium | Fondaparinux Sodium | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 11 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,201.98 · 41 records | Novo Nordisk Inc | AIRSUPRA, Cologuard Collection Kit, ELIQUIS, FARXIGA, GVOKE HYPOPEN, JOBST SPORT, NURTEC ODT, Ohtuvayre, Ozempic, Rybelsus, TRELEGY ELLIPTA, Wegovy, XIFAXAN, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error